AR-Q640X, a model to study the effects of constitutively active C-terminally truncated AR variants in prostate cancer cells

Springer Science and Business Media LLC - Tập 30 Số 3 - Trang 333-339 - 2012
Wolfgang Streicher1, Friedemann Zengerling1, Martin Laschak2, Wolfgang Weidemann2, Michael Höpfner3, Andres Jan Schrader1, Florian Jentzmik1, Mark Schrader1, Marcus V. Cronauer1
1Department of Urology, Research Laboratory, University of Ulm, Prittwitzstrasse 43, 89075, Ulm, Germany
2Institute of General Zoology and Endocrinology, University of Ulm, 89069 Ulm, Germany
3Institute of Physiology, Charité Berlin, 14195, Berlin, Germany

Tóm tắt

Từ khóa


Tài liệu tham khảo

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90

Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A (1995) Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res 55:3068–3072

Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A (1996) Androgen receptor status of lymph node metastases from prostate cancer. Prostate 28:129–135

Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinänen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi OP (1995) In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9:401–406

Cronauer MV, Schulz WA, Burchardt T, Anastasiadis AG, de la Taille A, Ackermann R, Burchardt M (2003) The androgen receptor in hormone-refractory prostate cancer: relevance of different mechanisms of androgen receptor signaling. Int J Oncol 23:1095–1102

Nadiminty N, Gao AC (2011) Mechanisms of persistent activation of the androgen receptor in CRPC: recent advances and future perspectives. World J Urol. doi: 10.1007/s00345-011-0771-3

Céraline J, Cruchant MD, Erdmann E, Erbs P, Kurtz JE, Duclos B, Jacqmin D, Chopin D, Bergerat JP (2004) Constitutive activation of the androgen receptor by a point mutation in the hinge region: a new mechanism for androgen-independent growth in prostate cancer. Int J Cancer 108:152–157

Libertini SJ, Tepper CG, Rodriguez V, Asmuth DM, Kung HJ, Mudryj M (2007) Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence. Cancer Res 67:9001–9005

Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ (2008) Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 68:5469–5477

Haile S, Sadar MD (2011) Androgen receptor and its splice variants in prostate cancer. Cell Mol Life Sci 68:3971–3981

Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, Matsumoto AM, Nelson PS, Montgomery RB (2011) Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 17:5913–5925

Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, Page ST, Coleman IM, Nguyen HM, Sun H, Nelson PS, Plymate SR (2010) Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 120:2715–2730

Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, Kim K, Sawyers CL (2010) Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci USA 107:16759–16765

Schütz SV, Schrader AJ, Zengerling F, Genze F, Cronauer MV, Mark Schrader M (2011) Inhibition of Glycogen Synthase Kinase-3β counteracts ligand-independent activity of the androgen receptor in castration resistant prostate cancer. PLoS ONE 6(9):e25341. doi: 10.1371/journal.pone.0025341

Mulholland DJ, Cox M, Read J, Rennie P, Nelson C (2004) Androgen responsiveness to renilla luciferase reporter vectors is promoter, transgene, and cell line dependent. Prostate 59:115–119

Rennie PS, Bruchovsky N, Leco KJ, Sheppard PC, McQueen SA, Cheng H, Snoek R, Hamel A, Bock ME, MacDonald BS, Nickel BE, Chang C, Liao S, Cattini PA, Matusik RJ (1993) Characterization of two cis-acting DNA-elements involved in the androgen regulation of the probasin gene. Mol Endocrinol 7:23–36

Jenster G, van der Korput HA, van Vroonhoven C, van der Kwast TH, Trapman J, Brinkmann AO (1991) Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol Endocrinol 5:1396–1404

Tepper CG, Boucher DL, Ryan PE, Ma AH, Xia L, Lee LF, Pretlow TG, Kung HJ (2002) Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res 62:6606–6614

Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB, Bova GS, Luo J (2009) Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 69:16–22

Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, Chen H, Kong X, Melamed J, Tepper CG, Kung HJ, Brodie AM, Edwards J, Qiu Y (2009) A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 69:2305–2313

Hörnberg E, Ylitalo EB, Crnalic S, Antti H, Stattin P, Widmark A, Bergh A, Wikström P (2011) Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS One 6(4):e19059. doi: 10.1371/journal.pone.0019059

Zhang X, Morrissey C, Sun S, Ketchandji M, Nelson PS, True LD, Vakar-Lopez F, Vessella RL, Plymate SR (2011) Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS One 6(11):e27970. doi: 10.1371/journal.pone.0027970

Hu R, Isaacs WB, Luo J (2011) A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities. Prostate 71:1656–1667

Lapouge G, Marcias G, Erdmann E, Kessler P, Cruchant M, Serra S, Bergerat JP, Céraline J (2008) Specific properties of a C-terminal truncated androgen receptor detected in hormone refractory prostate cancer. Adv Exp Med Biol 617:529–534

Bergerat JP, Céraline J (2009) Pleiotropic functional properties of androgen receptor mutants in prostate cancer. Hum Mutat 30:145–157

Andersen RJ, Mawji NR, Wang J, Wang G, Haile S, Myung JK, Watt K, Tam T, Yang YC, Banuelos CA, Williams DE, McEvan IJ, Wang Y, Sadar MD (2010) Regression of castrate- recurrent prostate cancer by small molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 17:535–546